MedTrace Logo

T-SPOT.CMV and T-SPOT.PRT Diagnostic Assays

NCT02382211 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2019-04-25

No results posted yet for this study

Summary

The T-SPOT assay quantifies the number of peripheral blood interferon-γ producing effector T cells \[spot forming cells/million peripheral blood mononuclear cells - PBMC)\]. The T-SPOT platform technology can be applied to diagnose and monitor any major disease process driven by a T cell response, including a viral disease such as cytomegalovirus (CMV) infection (the T-SPOT.CMV assay) or an allograft rejection (the T-SPOT.PRT assay).

Conditions

  • Infection in Solid Organ Transplant Recipients

Sponsors & Collaborators

  • Oxford Immunotec

    lead INDUSTRY

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2017-09-30
Completion
2017-09-30

Countries

  • United States
  • Canada
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02382211 on ClinicalTrials.gov